scholarly journals WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20–22 April 2021

Author(s):  
Margaret Liu ◽  
Tiequn Zhou ◽  
Rebecca Sheets ◽  
Heidi Meyer ◽  
Ivana Knezevic
1998 ◽  
Vol 163 (5) ◽  
pp. 324-330 ◽  
Author(s):  
G. David Young ◽  
Sandra Evans

Abstract Many preventable diseases affecting troop strength are directly attributed to disease-carrying insects. The first line of defense against arthropod vectors is the use of personal protective measures. The concurrent application of DEET (N,N-diethyl-m-toluamide) repellent on the skin and permethrin [(3-phenoxy-phenyl)methyl(±)cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-carboxylate] insecticide on the battle dress uniform, while the uniform is worn properly, is a personal protective strategy officially known as the DOD Insect Repellent System. It is important for troop commanders and field leaders to enforce the use of personal protective measures to prevent insect-borne infectious diseases and to ensure troop and soldier readiness. DEET is a safe and effective repellent. Permethrin is a synthetic pyrethroid insecticide and repellent. Used in conjunction with proper clothing and other personal protective equipment, these repellents provide the best known protection available and are critical in minimizing the occupational health threat of arthropod-borne diseases to troops in the field.


2003 ◽  
Vol 58 (5) ◽  
pp. 263-274 ◽  
Author(s):  
Lucia Ferro Bricks

Neonates and young children remain susceptible to many serious infectious diseases preventable through vaccination. In general, current vaccines strategies to prevent infectious diseases are unable to induce protective levels of antibodies in the first 6 months of life. Women vaccinated during pregnancy are capable of producing immunoglobulin antibodies that are transported actively to the fetus, and maternal immunization can benefit both the mother and the child. With few exceptions, maternal immunization is not a routine, because of the concerns related to the safety of this intervention. Ethical and cultural issues make the studies on maternal immunization difficult; however, in the last decade, the development of new vaccines, which are very immunogenic and safe has reactivated the discussions on maternal immunization. In this paper we present a review of the literature about maternal immunization based on MEDLINE data (1990 to 2002). The most important conclusions are: 1) there is no evidence of risk to the fetus by immunizing pregnant women with toxoids, polysaccharide, polysaccharide conjugated and inactive viral vaccines; 2) most viral attenuated vaccines are probably safe too, but data is still insufficient to demonstrate their safety; therefore these vaccines should be avoided in pregnant women; 3) in Brazil, there is a need for a maternal immunization program against tetanus. Many new candidate vaccines for maternal immunization are available, but studies should be conducted to evaluate their safety and efficacy, as well as regional priorities based on epidemiological data.


2021 ◽  
Vol 20 (2) ◽  
pp. 463-464
Author(s):  
Musa Mohd Nordin ◽  
Husna Musa

As the number of COVID-19 cases continues to rise with over 65 million recorded cases and more than 1.5 million mortalities as of early December, the race against time to find a vaccine intensifies. In recent years, there has been growing interest in mRNA-based technology for the development of prophylactic vaccines against infectious diseases and even for cancers and allergies. The prospects for mRNA vaccines are very promising because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, until now, no vaccines using this technology have made it this far in clinical trials thus there have been concerns on the therapeutic and possible adverse effects and claims especially on social media that the vaccines will alter the DNA. This article discusses the unique attributes of mRNA vaccines and current challenges and expectations within the context of the COVID-19 pandemic. Bangladesh Journal of Medical Science Vol.20(2) 2021 p.463-464


2014 ◽  
Vol 44 (3) ◽  
pp. 107-111 ◽  
Author(s):  
C. Rameau ◽  
S. Mahy ◽  
A.-L. Simonet Lamm ◽  
A. Fillion ◽  
M. Buisson ◽  
...  

2021 ◽  
Vol 25 ◽  
pp. 798-806
Author(s):  
Sejabaledi A. Rankoana

The purpose of this study was to describe the indigenous plant-derived medicine used to treat symptoms related to four of the most common symptoms of the COVID-19 pandemic. Data presented in this study form part of a medical ethnobotanical study conducted in Limpopo Province, South Africa between 2012 and 2019. The study recorded 89 plant species identified as sources of medicine. Of these plants, 13 species belonging to 9 botanical families were used as sources of medicine to cure influenza, cough, sore throat and fever, while 5 species belonging to 5 botanical families were sources of preventive medicine. The treatment of the four symptoms is accomplished through the administration of oral decoctions, steaming and infusions, while preventive medicine is in the form of infusion, decoction, chew or charm, which is used to prevent susceptibility to infectious diseases such as influenza and cough.  Knowledge of these medicines rests with ordinary community members who offer treatment after observations of the symptoms on their family members. The indigenous plant-derived medicines identified in this study may be tested for their safety and efficacy to discover new local, affordable and culture-specific drugs that could be used in the modern phytotherapy for conditions such as COVID-19.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1570
Author(s):  
Jong-Woo Lim ◽  
Yu-Rim Ahn ◽  
Geunseon Park ◽  
Hyun-Ouk Kim ◽  
Seungjoo Haam

The coronavirus disease (COVID-19) pandemic poses serious global health concerns with the continued emergence of new variants. The periodic outbreak of novel emerging and re-emerging infectious pathogens has elevated concerns and challenges for the future. To develop mitigation strategies against infectious diseases, nano-based approaches are being increasingly applied in diagnostic systems, prophylactic vaccines, and therapeutics. This review presents the properties of various nanoplatforms and discusses their role in the development of sensors, vectors, delivery agents, intrinsic immunostimulants, and viral inhibitors. Advanced nanomedical applications for infectious diseases have been highlighted. Moreover, physicochemical properties that confer physiological advantages and contribute to the control and inhibition of infectious diseases have been discussed. Safety concerns limit the commercial production and clinical use of these technologies in humans; however, overcoming these limitations may enable the use of nanomaterials to resolve current infection control issues via application of nanomaterials as a platform for the diagnosis, prevention, and treatment of viral diseases.


Sign in / Sign up

Export Citation Format

Share Document